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Jean Dausset (1916–2009)‘‘Science is like a web, growing
by interactions that reach out in
time and space. My own place in
this web was made possible by
strands from the past and the help
of contemporaries.’’ George Snell
Nobel lecture (1980)
The pioneering work of Jean Dausset,
who passed away on June 6, 2009, led
to the discovery of the human leukocyte
antigen. This breakthrough, for which he
shared the 1980 Nobel Prize in Medicine
with Baruj Benacerraf and George Snell,
opened a new area in medicine.
The Initial Experiments
Jean Dausset was born on October 19,
1916 in Toulouse, a city in the south of
France, and at the age of 11, settled in
Paris. His interest in hematology and
what would soon become immunoge-
netics started shortly after he graduated
as a medical doctor in Paris. One of his first
professional experiences was in a ‘‘trans-
fusion unit’’ during World War II, in North
Africa. Shortly after his return to liberated
France, Dausset made his seminal
observation by detecting the presence
of ‘‘leuco-agglutinins’’ in the serum of
a patient with chronic agranulocytosis
who received multiple transfusions
(Dausset and Nenna, 1952). Although
empirical demonstration was lacking at
the time, he would always refer to this
observation as the moment he under-
stood that something important was
happening with the serum. In subse-
quent studies, he observed that the
antibodies targeting leukocytes differed
from the ABO system on red blood cells
(Dausset, 1958). Because the sampling
was large enough, he reached several
important conclusions: these anti-
bodies were inactive on the patient’s
own leukocytes but agglutinated the
white blood cells from a variety of other
patients. This observation alone, wrote
Dausset, is sufficient to demonstrate
that there are important antigenic differ-
ences between individuals and that
these differences form ‘‘leukocyte
groups.’’ He suggested that these anti-
gens were at the cell surface and that
they increased with the number oftransfusions. He would call the antigen
MAC (initials of the name of the three
patients of whom the white blood cells
were not agglutinated by the serum of
a polytransfused patient), later renamed
the human leukocyte antigen-A2 (HLA-
A2). In the same paper, Dausset also sug-
gested the extreme variability of human
leukocyte antigens and the way they
were inherited, suggesting here, too, the
importance of studying leukocyte antigens
for tissue transplantation and particularly
for bone marrow transplantation. Dausset
insisted upon a strong collaborative
approach of science. The organization of
yearly meetings on HLA, with the
exchange of ideas and material, contrib-
uted enormously to the advances in the
field.
The Historical Context of MHC
Discovery
The history of histocompatibility started at
the beginning of the 20th century, first at
Harvard University (USA), then at the
Jackson laboratory (USA) with the exper-
iments of Ernest Tyzzer and Clarence
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by genes showing Mendelian inheritance.
Peter Gorer from Guy’s hospital in London
discovered the H2 and, together with the
studies of George Snell, provided the
basis for the major histocompatibility
complex (MHC) genetics in mice. The
discovery that just a few, but very poly-
morphic, genes control tissue rejection
as well as antibody and lymphocyte reac-
tivity in man and mouse explained some
mystery of the genetics. However, one still
had to understand what was the normal
function of these genes. Hugh McDevitt
and Baruj Benacerraf, among others,
had previously found that the ability of
animals to react with certain antigens
was controlled by so-called immune
response (Ir) genes. It turned out that Ir
genes comapped and were the genes of
the MHC. Moreover, this same set of
genes controlled the ability of T cells to
interact with B cells and antigen-present-
ing cells, leading some to believe that
MHC genes coded for the receptors for
antigen on T cells (Kindred and Shreffler,
1972; Rosenthal and Shevach, 1973).
This view was derailed by findings in
the 1970s showing that MHC products
are expressed primarily on B cells, but
not T cells. The confusion was clarified
and settled by the demonstration by
Rolf Zinkernagel and Peter Doherty
that T cells had to somehow recognize
both the antigen and an MHC product
on another cell in order to respond
properly. T cells could react with
antigen and MHC by using two different
receptors, or just one. The second
possibility seemed unlikely in the
1970s, given that it required MHC to
have a seemingly unlimited ability to
combine with the universe of antigens.
However, the construction of T cells
bearing two different receptors, one
able to react with MHC x and antigen x
and the other with MHC y and antigen
y, solved the problem. It turned out the
two-receptor T cells could not react
with the mixed combinations, that is
MHC x plus antigen y or vice versa.
This result showed that the unlikely
possibility of a single receptor for
antigen and MHC was correct (Kappler
et al., 1981). Thus, MHC proteins had to1, August 21, 2009 ª2009 Elsevier Inc. 171
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gens, but how? The groups of Emil Un-
anue and Howard Grey showed that the
antigens involved were in fact peptides.
The solution to the problem posed by the
ability of MHC proteins to bind to many
different peptides came ultimately from
solved structures of MHC, pioneered by
Pamela Bjorkman working as a graduate
student in the laboratory of Don Wiley.
So finally after many twists and turns in
the route to our understanding on the
MHC, the problems were almost solved.
The mysterious molecules identified by
Dausset in man were proteins, whose job
is to bind peptides from foreign material
and then be recognized, as a combination,
by T cells that thereafter orchestrate the
elimination of the source of peptide.
MHC and Disease Predisposition
Discovery and characterization of HLA
system was a major watershed both for
human genetics and genetics in general.
For the first time there was a complex
system of biologically highly relevant
genes that were likely to be involved in
control of a variety of biological traits. It
is a testimony of the vision of Jean Daus-
set that he strongly perceived from the
very beginning that the potential offered
by HLA discovery exceeds the field
of transplantation immunology and will
soon cover broad areas of disease predis-
position. He believed that it foreshadows
existence of many yet-to-be-discovered
genes that determine individual’s predis-
position to disease. More than that, he
and his colleagues recognized that our
genes not only determine our propensity
to contract a certain disease, but also
are an important nosologic criterion in dis-
tinguishing between clinically similar
diseases (Cann et al., 1987). The recogni-
tion that the spread of genotypes in the
population influences the distribution of
individual risk and also can lead to often
fundamentally different forms of appar-
ently ‘‘same’’ diseases is gaining full
appreciation only now.
The fascination with the HLA by scien-
tists from different fields immediately after
its discovery was caused by several
factors. It was the only defined genetic
system with broad biological effects and
there were no other genes with similar
attraction. But it was also the unparalleled
polymorphism of HLA genes and their
biological heterogeneity and complexity172 Immunity 31, August 21, 2009 ª2009 Elsthat suggested that they might play an
important role in a variety of biological
processes. Indeed the first decade after
its discovery revealed influence of HLA on
a variety of diseases (Ryder et al., 1981).
Presently we know that the complexity of
MHC, composed of more than 100 genes
compressed in ± 3.6 Mb, far exceeds the
original estimates. This high gene density
also makes the main method of detecting
disease predisposition genes—mapping
by association—extremely difficult. Some
diseases are caused by mutations of
genes in the MHC that are not related to
any of the three major MHC classes—
e.g., hemochromatosis and HFE gene,
congenital adrenal hyperplasia, and 21-
hydroxylase. However, the largest number
of diseases is associated with the main
MHC genes—Class I, Class Ib, Class II,
and Class III (complement genes)—and
they are related to a distortion of the
immune response. This impact on regula-
tion of homeostasis of the immune system
is not surprising because class I and class
II molecules present antigens to T lympho-
cytes and the complement system is
involved in lysing infecting agents or pro-
cessing of antigen-antibody complexes.
Determination of HLA types in affected
persons can help to diagnose the disease
and assess the prognosis.
The progress in defining HLA-disease
associations led to the recognition of
virtually all major general characteristics
of disease predisposition genes and
turned out to also be valid for suscepti-
bility genes that were discovered later, in
the genomic era, by linkage analysis or
genome-wide association studies. The
genetic predisposition to disease is multi-
factorial, caused by several low-pene-
trance genes, which alone can only rarely
cause the disease. The effects of rela-
tively strong genes are modified by the
environment, but also by other genes. In
addition, the specific features of the
MHC that contains a number of genes
affecting various aspects of immune
response is responsible of the phenom-
enon of linkage disequilibrium and exis-
tence of superhaplotypes. These unique
nonrandom combinations of alleles at
a number of linked MHC genes are specif-
ically associated with certain diseases,
indicating a possible involvement of
several linked genes or an undetected
mutation that occurred after the haplo-
type became fixed in the population.evier Inc.Building the Future at the CEPH
The main interest of Dausset was to under-
stand the molecular basis of human poly-
morphism. With He´le`ne Anavy’s legacy,
from her superb art collection sold at So-
theby’s to support his research, Dausset
founded with Daniel Cohen the Centre
d’Etude du Polymorphisme Humain
(CEPH). Cohen started some of the most
beautiful work in genetics with Howard
Cann, Mark Lathrop, Jean Weissenbach,
Jacques Beckmann, and Ilya Chumakov,
leading to the physical and genetic map
of the human genome (Chumakov et al.,
1995), the genome diversity project, and
the discovery of predisposition genes for
diseases such as hypertension, diabetes,
myopathies, and cancer. With a small but
well-organized and well-funded structure,
this group challenged the scientific
community and pushed the discovery of
the human genome, hence contributing
in a major way to modern medicine.
In spite of new tools, many questions
remain to be solved. Although the HLA-
predisposing genes have relatively strong
penetrance, many of the predisposing
genes detected by genome-wide associ-
ation studies have low penetrance, in-
creasing the odds ratio 1.2–1.4 times.
For widely studied diseases, it seems
that most genes with effects of this size
have been already detected (Tomlinson
et al., 2008). Detection of genes with
even smaller effects requires much larger
studies, which will probably result in less
precise mapping. Also, the results of
association studies fail to explain familial
clustering of diseases (Ahmed et al.,
2009).
In 1994, two of us (A.T. and R.A.) joined
the CEPH to develop the cancer genetics
program and have enjoyed its superb
scientific environment. Dausset and
Cohen’s support of our tumor reversion
project was unconditional. Equal to our
enthusiasm for science was our shared
passion for literature and art. We would
often discuss what art and science have
in common—creativity—and we would
spend endless hours discussing the work
of Artaud, Tanguy, Brauner, Dali, Cama-
cho, and Matta. In fact, Jean Dausset
had,withhis firstwife, anart gallery inParis,
in Saint Germain des Pre´s. After World War
II, painters, poets, and writers used to drop
by and have dinner at their house.
Jean Dausset showed insatiable curi-
osity and open mindedness toward other
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impressive as both a Nobel laureate and
one of the most influential French scien-
tific personalities, Jean Dausset was
very approachable, always available and
eager to listen and provide some
constructive advice. Although he stood
very critically about results in the lab, his
remarks were always extremely helpful
to all of us. He disdained dishonesty,
but taught us to trust people without
restraint. Jean Dausset was a mentor,
for all of us.
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